Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Zwaginga, J.J.; Holt, B. van der; Boekhorst, P.A. te; Biemond, B.J.; Levin, M.D.; Griend, R. van der; ... ; Dutch HOVON 64 Study Grp (2015)

Article / Letter to editor

• immune thrombocytopenia
• rituximab
• splenectomy delaying
• early response
• open label phase II

• All authors: Zwaginga, J.J.; Holt, B. van der; Boekhorst, P.A. te; Biemond, B.J.; Levin, M.D.; Griend, R. van der; Brand, A.; Zweegman, S.; Pruijt, H.F.M.; Novotny, V.M.J.; Vreugdenhil, A.; Groot, M.R. de; Weerdt, O. de; Pampus, E.C.M. van; Maanen-Lamme, T.M. van; Wittebol, S.; Schipperus, M.R.; Silbermann, M.H.; Huijgens, P.C.; Luten, M.; Hollestein, R.; Brakenhoff, J.A.C.; Schrama, J.G.; Valster, F.A.A.; Velders, G.A.; Koene, H.R.; Dutch HOVON 64 Study Grp
• Date: 2015-03-31
• Journal: Haematologica
• Volume: 100
• Issue: 3
• Pages: E90 - E92
• DOI: doi:10.3324/haematol.2014.110213